Skip to main content
Premium Trial:

Request an Annual Quote

Welcome to Information Overload

Daniel MacArthur at Genetic Future has a post about whether there will be value in sequencing the full genome of each newborn in the next decade. "There are plenty of very rare, severe disease mutations that would be clinically useful to detect at an early stage," he writes. "Secondly, pharmacogenomics is finally coming of age." He notes that advances from GWAS have begun to make the PGx field more viable, citing abacavir and statins as examples of drugs that can be kept away from patients who will have major adverse reactions "by typing a single genetic marker."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.